# Cancer Peptide Vaccines Sector

Canonical URL: https://biopharmsignal.com/sector/cancer-peptide-vaccines

Cancer Peptide Vaccines includes companies developing peptide-based therapeutic vaccines for oncology. These programs are designed to train the immune system against tumor-associated or tumor-specific antigens and are often paired with broader immunotherapy strategies.

Companies currently grouped under Cancer Peptide Vaccines: 2

## Recent Sector News

- 2026-07-20 10:00 EST — GLSI — [Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-clinical-updates-on-flamingo-01-99f074c4) — Source: Greenwich LifeSciences
- 2026-07-16 11:30 EST — GLSI — [Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-european-approval-for-combining-both-hla-popula-adf83f60) — Source: Greenwich LifeSciences
- 2026-07-09 10:00 EST — GLSI — [Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-european-approval-for-use-of-commercially-manuf-3adb0b48) — Source: Greenwich LifeSciences
- 2026-06-25 13:46 EST — GLSI — [Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-presents-flamingo-01-phase-iii-trial-open-label-data-published-at-asco-meeting-2026) — Source: Greenwich LifeSciences
- 2026-06-25 13:46 EST — GLSI — [Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-receipt-of-nasdaq-notice-regarding-late-form-10-q-filing) — Source: Greenwich LifeSciences
- 2026-06-25 13:46 EST — GLSI — [Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-use-of-commercially-manufactured-gp2-in-flamingo-01) — Source: Greenwich LifeSciences
- 2026-06-25 13:46 EST — GLSI — [Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-update-showing-continued-reduction-in-recurrence-rate-in-the-open-label-arm-of-flamingo-01) — Source: Greenwich LifeSciences
- 2026-06-25 13:46 EST — GLSI — [Greenwich LifeSciences Provides Update on Upcoming AACR Meeting](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-update-on-upcoming-aacr-meeting) — Source: Greenwich LifeSciences
- 2026-06-25 13:46 EST — GLSI — [Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-addition-of-city-of-hope-to-flamingo-01) — Source: Greenwich LifeSciences
- 2026-06-25 13:46 EST — GLSI — [Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-update-on-patent-claims-potentially-doubling-gp2-market-potential) — Source: Greenwich LifeSciences
- 2026-06-25 13:46 EST — GLSI — [Greenwich LifeSciences Provides Update on Financing Strategy](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-update-on-financing-strategy) — Source: Greenwich LifeSciences
- 2026-06-25 13:46 EST — GLSI — [Greenwich LifeSciences Provides Update Regarding Form 10-K Filing](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-update-regarding-form-10-k-filing) — Source: Greenwich LifeSciences
- 2026-06-25 13:46 EST — GLSI — [Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-acceptance-of-abstract-at-asco-2026) — Source: Greenwich LifeSciences
- 2026-06-25 13:46 EST — GLSI — [Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-receipt-of-nasdaq-notice-regarding-late-form-10-k-filing) — Source: Greenwich LifeSciences
- 2026-06-25 13:46 EST — GLSI — [Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-presents-flamingo-01-phase-iii-trial-open-label-data-published-at-aacr-meeting-2026) — Source: Greenwich LifeSciences
- 2026-06-01 10:00 EST — GLSI — [Greenwich LifeSciences Provides Update Regarding Form 10-K Filing](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-update-regarding-form-10-k-filing-5fb4f975) — Source: Greenwich LifeSciences

## Companies

- [GLSI](https://biopharmsignal.com/company/GLSI) — Greenwich LifeSciences
- [PDSB](https://biopharmsignal.com/company/PDSB) — PDS Biotechnology Corporation